The new edition, titled “Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)”, offers comprehensive recommendations on key ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

No treatments currently exist for the fatty liver disease, but the market could be worth $40 billion in less than 10 years. While most interest was shown in Novartis’ oncology pipeline at its ...

Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be ...

The guidelines also emphasise that the diet should have 1,200 to 1,800 kilocalories per day or 500-700 kilocalories less ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...

Unexpectedly, the study found that lean patients with NAFLD had a higher risk of developing heart disease than non-lean ...

Non-Alcoholic Fatty Liver Disease (NAFLD), now termed Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), is rising ...

Fatty liver has become a growing health concern. Experts have enlisted a set of rules that can help reducing the excess fat ...

It broadened our traditional understanding of how triglycerides and cholesterol are regulated during the progression of NAFLD." Currently, treatment options for NAFLD are limited; the main ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...